VivoSeq
Oncology

Leiomyosarcoma

36

Pipeline Programs↗

12

Active Trials↗

21

Companies Involved↗

Leiomyosarcoma is a moderately active landscape with 36 programs across 21 companies. The most active players are Eisai, Eli Lilly, Bristol-Myers Squibb. 2 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

19/100

Mech. Concentration

16/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

31 of 39 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody513%Protein / enzyme38%

Small molecule leads; the ring shows all 39 classified programs, each share of the total. Modality classified for 100% of 39 pipeline programs.

Analysis

Trial Status

36

clinical trials

Completed15 · 42%
Recruiting9 · 25%
Unknown status4 · 11%
Terminated3 · 8%
Active, not recruiting2 · 6%
Withdrawn2 · 6%
Other1 · 3%

Clinical Trials

Trial Activity

36 trials

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Recruiting·—·Phase 2·NCT06528769·16 enrolled
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06308419·18 enrolled
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Recruiting·IItalian Sarcoma Group·Phase 2·NCT04383119·100 enrolled
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Recruiting·WWashington University School of Medicine·Phase 1·NCT06957431·18 enrolled
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
Recruiting·NNorthwestern University·Phase 2·NCT06571734·29 enrolled
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT07125183·20 enrolled
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Recruiting·PPharmaMar·Phase 3·NCT06088290·450 enrolled
Pilot Study of ctDNA and Imaging Characteristics as Biomarkers of Disease-related Outcomes in Patients With Localized Leiomyosarcoma Receiving Chemotherapy
Recruiting·UUniversity of Michigan Rogel Cancer Center·N/A·NCT04925089·40 enrolled
Observational Study of Biomarkers of Disease-related Outcomes in Patients With Metastatic Leiomyosarcoma Receiving Chemotherapy
Recruiting·UUniversity of Michigan Rogel Cancer Center·N/A·NCT05653388·200 enrolled
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04624178·20 enrolled
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Active, not recruiting·MMassachusetts General Hospital·Phase 1/2·NCT05099666·62 enrolled
A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy
Enrolling by invitation·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT07405346·50 enrolled
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
Completed·PPTC Therapeutics·Phase 1·NCT03761095·41 enrolled
A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Completed·YYonsei University·Phase 2·NCT03810976·37 enrolled
Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00614835·25 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)